Skip to main content
. 2024 Aug 20;15(9):e02043-24. doi: 10.1128/mbio.02043-24

Fig 3.

Inflammatory response in WT and ASB3 mice with DSS treatment: mRNA levels, protein levels, and cytokine expression. Includes IL-1β, IL-6, TNF-α mRNA and protein levels, IκBα phosphorylation, IL-22+ ILC3 counts, and heatmap of genes.

ASB3 deficiency inhibits the synthesis and release of proinflammatory cytokines. (a and b) Volcano plots and heatmap of RNA-seq data show upregulated or downregulated expression of genes in colon tissues from WT (n = 3) and ASB3−/− mice (n = 3) treated with 3% DSS. (c) qPCR analysis of IL-1β, IL-6, and TNF-α mRNA expression in colon tissue sections from WT (n = 5) and ASB3−/− mice (n = 5) treated with 3% DSS. (d) Colonic secretion of cytokines. (e and f) The expression of p-IκBα, IκBα, ASB3, and β-actin proteins in colon tissues from WT (n = 6) and ASB3−/− mice (n = 5) treated with or without 3% DSS was detected by Western blotting. (g) Frequencies of ILC3s in cLPLs from WT and ASB3−/− mice treated with or without 3% DSS. (h) Proportions of IL-22+ ILC3 cells in the colon of WT (ASB3+/+) and ASB3−/− mice treated with 3% DSS. (i) Frequencies and absolute number of IL-22+ ILC3s in cLPLs from WT (n = 9) and ASB3−/− (n = 9) mice treated with 3% DSS. (j) The mRNA expression levels of IL-22 were determined by qPCR assay. Differences were determined in panels b, c, d, and f by unpaired Student’s t test and in panels a and g by one-way ANOVA.